Singapore markets closed

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.4600+0.3200 (+7.73%)
At close: 04:00PM EDT
4.3500 -0.11 (-2.47%)
Pre-market: 09:20AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.1400
Bid4.3100 x 4000
Ask4.4300 x 2200
Day's range4.1400 - 4.4750
52-week range3.6000 - 10.9910
Avg. volume3,005,612
Market cap474.499M
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Why Coherus BioSciences Stock Was Plunging This Week

    Unfortunately for shareholders of Coherus BioSciences (NASDAQ: CHRS), that's what happened to their company after market hours last Friday. Following that, its stock price was falling by 10% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence. Among these incoming S&P SmallCap 600 constituents are pizza slinger Papa John's International, storied athletic apparel retailer Foot Locker, and JetBlue Airways.

  • Motley Fool

    Why Coherus BioSciences Stock Popped Today

    Shares of Coherus BioSciences (NASDAQ: CHRS) soared 17.7% on Thursday, according to data provided by S&P Global Market Intelligence, after the biotech company announced better-than-expected quarterly results. Coherus' net revenue climbed a whopping 81% year over year to $58.7 million, translating to an adjusted net loss of $32.8 million, or $0.38 per share. Analysts, on average, were anticipating a wider net loss of $0.48 per share on lower revenue of $50.5 million.

  • Zacks

    Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

    Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 26.92% and 15.53%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?